N-gly sites identified in the major clone of 6 patients with FL taken at different time points of disease
| Patient . | Disease event . | No. of N-gly sites . | Region in IGHV . | AA position of N-gly site . | N-gly motif in major clone . | Percentage of unique subclones with N-gly site of major clone present . |
|---|---|---|---|---|---|---|
| 1 | Diagnosis | 1 | CDR3 | 108 | NFS | 98.31 |
| Transformation | 1 | CDR3 | 108 | NVS | 98.17 | |
| 2 | 1st relapse | 4 | CDR1, FR2, CDR2, FR3 | 30, 39, 56, 85 | NFS, NMS, NIT, NNS | 99.01, 99.01, 98.87, 97.22 |
| 3rd relapse | 4 | CDR1, FR2, CDR2, FR3 | 30, 39, 56, 85 | NFS, NMS, NIT, NNS | 99.31, 96.8, 98.75, 81.83 | |
| Transformation | 4 | CDR1, FR2, CDR2, FR3 | 30, 39, 56, 85 | NFS, NMS, NIT, NNT | 98.54, 98.16, 97.71, 84.95 | |
| 3 | 2nd relapse | 1 | CDR2 | 56 | NIS | 97.47 |
| 3rd relapse | 1 | CDR2 | 56 | NIS | 97.91 | |
| Transformation | 1 | CDR2 | 56 | NIS | 98.18 | |
| 4 | 1st relapse | 2 | FR2, CDR3 | 48, 108 | NKS, NNS | 97.53, 100 |
| 2nd relapse | 2 | FR2, CDR3 | 48, 108 | NKS, NNS | 97.98, 99.6 | |
| 5 | 1st relapse | 1 | CDR1 | 30 | NFS | 97.14 |
| 3rd relapse | 1 | FR3 | 94 | NLT | 99.19 | |
| 6 | FL diagnosis | 1 | CDR3 | 108 | NGS | 98.41 |
| tFL diagnosis | 1 | CDR3 | 108 | NGS | 97.94 | |
| tFL relapse | 1 | CDR3 | 108 | NGS | 96.74 |
| Patient . | Disease event . | No. of N-gly sites . | Region in IGHV . | AA position of N-gly site . | N-gly motif in major clone . | Percentage of unique subclones with N-gly site of major clone present . |
|---|---|---|---|---|---|---|
| 1 | Diagnosis | 1 | CDR3 | 108 | NFS | 98.31 |
| Transformation | 1 | CDR3 | 108 | NVS | 98.17 | |
| 2 | 1st relapse | 4 | CDR1, FR2, CDR2, FR3 | 30, 39, 56, 85 | NFS, NMS, NIT, NNS | 99.01, 99.01, 98.87, 97.22 |
| 3rd relapse | 4 | CDR1, FR2, CDR2, FR3 | 30, 39, 56, 85 | NFS, NMS, NIT, NNS | 99.31, 96.8, 98.75, 81.83 | |
| Transformation | 4 | CDR1, FR2, CDR2, FR3 | 30, 39, 56, 85 | NFS, NMS, NIT, NNT | 98.54, 98.16, 97.71, 84.95 | |
| 3 | 2nd relapse | 1 | CDR2 | 56 | NIS | 97.47 |
| 3rd relapse | 1 | CDR2 | 56 | NIS | 97.91 | |
| Transformation | 1 | CDR2 | 56 | NIS | 98.18 | |
| 4 | 1st relapse | 2 | FR2, CDR3 | 48, 108 | NKS, NNS | 97.53, 100 |
| 2nd relapse | 2 | FR2, CDR3 | 48, 108 | NKS, NNS | 97.98, 99.6 | |
| 5 | 1st relapse | 1 | CDR1 | 30 | NFS | 97.14 |
| 3rd relapse | 1 | FR3 | 94 | NLT | 99.19 | |
| 6 | FL diagnosis | 1 | CDR3 | 108 | NGS | 98.41 |
| tFL diagnosis | 1 | CDR3 | 108 | NGS | 97.94 | |
| tFL relapse | 1 | CDR3 | 108 | NGS | 96.74 |
Italic text in bold refers to differences in the location or amino acid (aa) sequence of N-gly sites, referred to as N-gly motif, within the major clone across temporal samples. The major clone was determined by the highest count number. The multiple values in patient 2 and 4 relate to the multiple N-gly sites observed. The majority of subclones across patients and disease events retain the N-gly site of the major clones (P < .0001). AA, amino acid. Numbers given under the heading “AA position of N-gly site” refer to the position of the middle AA making up the N-gly site, according to IMGT numeration of the variable region.